Report Highlights

U.S. Cell Harvesting: Competitive Overview

The U.S. cell harvesting market is moderately concentrated, with the top four players — Thermo Fisher Scientific, Sartorius AG, Danaher Corporation, and Merck KGaA — collectively commanding an estimated 58% of total revenue in 2024. Competitive advantage in this market is determined by platform integration depth, consumable lock-in strategies, and the ability to offer end-to-end bioprocessing workflows rather than standalone instruments. Domestic players such as Pall Corporation (now Danaher) benefit from deep relationships with established U.S. biopharma manufacturers, while international entrants leverage pricing and innovation in single-use technologies to gain ground in contract development and manufacturing organizations.

International companies, particularly Sartorius and Merck KGaA, have invested significantly in U.S.-based manufacturing and service infrastructure to reduce procurement lead times and meet FDA supply-chain expectations for GMP-grade equipment. The competitive split between domestic and multinational players is roughly 40:60 in favor of multinationals, driven by their superior R&D pipelines and broader product portfolios. Winning in this market requires validated regulatory compliance documentation, proven scalability from bench to commercial scale, and established field service networks across key U.S. biopharma hubs including Boston, San Diego, and Research Triangle Park.

Demand Drivers Shaping Cell Harvesting in the U.S.

The rapid commercial expansion of cell and gene therapy manufacturing is the most powerful structural driver reshaping competitive positioning in U.S. cell harvesting. FDA approval of multiple CAR-T therapies from Novartis, Kite Pharma, and Bristol-Myers Squibb has created sustained procurement demand for closed, automated harvesting systems capable of maintaining cell viability above 90%. Players with validated CAR-T-compatible workflows — specifically Thermo Fisher's CTS Rotea Counterflow Centrifugation System and Sartorius's BIOSTAT platforms — are capturing disproportionate contract manufacturing organization volumes as CDMOs scale up U.S. capacity in anticipation of pipeline approvals through 2028.

A second major driver is the scaling of mRNA and viral vector manufacturing in response to pandemic-era infrastructure investments, which has carried forward into oncology and rare disease programs. This favors suppliers with depth in tangential flow filtration and continuous bioprocessing technologies. Third, the NIH's sustained funding of basic research — exceeding USD 47 billion annually — keeps academic demand for mid-throughput cell harvesters stable, benefiting mid-market players like PerkinElmer and Tecan that serve laboratory settings where cost sensitivity limits premium platform adoption. Each driver skews competitive advantage toward different tiers of the market, preventing full consolidation.

Competitive Restraints and Market Challenges

Pricing pressure is intensifying across the mid-tier segment of the U.S. cell harvesting market as Chinese instrument manufacturers — particularly those supplying OEM components through distribution agreements — undercut established Western suppliers on benchtop harvesting units by 20–35%. This erosion forces incumbents to compete on service contracts and software integration rather than hardware alone, compressing gross margins on entry-level systems. Simultaneously, the high capital cost of transitioning to fully automated closed-system platforms creates procurement cycle delays, particularly among mid-sized biotech firms operating under tight cash runway constraints in the current funding environment.

Regulatory compliance costs represent a structural burden that disproportionately impacts smaller U.S. competitors. Meeting FDA 21 CFR Part 11 electronic record requirements, current Good Manufacturing Practice validation protocols, and the increasingly stringent biosafety standards for viral vector applications requires sustained quality assurance investment that only well-capitalized players can sustain profitably. Talent shortages in bioprocess engineering — particularly in automated systems validation and bioreactor operations — further constrain market expansion, as end-users delay purchasing decisions when they cannot staff systems adequately. These combined pressures favor established multinational players with integrated field support and application specialist teams already embedded in U.S. customer sites.

Growth Opportunities for Market Players

The buildout of decentralized cell therapy manufacturing — driven by logistics challenges in autologous CAR-T production — presents a high-value opportunity for compact, point-of-care-compatible harvesting systems. Companies capable of delivering GMP-compliant, closed-system harvesting in a footprint suitable for hospital-based manufacturing suites stand to capture a market segment that remains structurally underserved. Ori Biotech and Cellares are actively developing modular manufacturing platforms that require integrated harvesting modules, creating partnership opportunities for established harvesting technology providers willing to co-develop or white-label their systems for next-generation cell therapy factories operating in U.S. academic medical centers.

Single-use technology adoption in large-scale U.S. biomanufacturing is accelerating, with single-use bioreactor installations projected to outpace stainless-steel installations at major CDMOs by 2027. This transition creates recurring consumable revenue streams that are structurally more defensible than capital equipment sales alone. Players that establish multi-year consumable supply agreements with large-volume CDMOs — such as Lonza's U.S. operations or Samsung Biologics' New Jersey facility — will build revenue floors that competitors without installed bases cannot easily displace. The combination of recurring consumable pull-through and embedded service contracts represents the clearest path to sustained margin expansion in this market through 2032.

Market at a Glance

Leading Market Participants

• Thermo Fisher Scientific
• Sartorius AG
• Danaher Corporation (Pall Corporation)
• Merck KGaA (MilliporeSigma)
• BD Biosciences
• PerkinElmer
• Tecan Group
• Repligen Corporation
• Lonza Group
• Celltrio (formerly Cesca Therapeutics)

Regulatory and Policy Environment

The FDA's Center for Biologics Evaluation and Research (CBER) is the primary regulatory authority governing cell harvesting equipment used in therapeutic applications, enforcing compliance under 21 CFR Parts 210, 211, and 820 for device manufacturers supplying GMP environments. The FDA's 2021 Guidance on Chemistry, Manufacturing, and Controls for Human Gene Therapy Investigational New Drug Applications directly elevated documentation and traceability requirements for harvesting systems used in viral vector and cell therapy pipelines, increasing validation costs for all market participants and raising entry barriers for new competitors without established regulatory affairs infrastructure in the United States.

The Inflation Reduction Act and the CHIPS and Science Act have indirectly bolstered NIH and BARDA funding channels supporting domestic biomanufacturing investment, creating procurement tailwinds for U.S.-compliant harvesting equipment suppliers. The National Institute of Standards and Technology's biomanufacturing initiative is further driving standardization of cell harvesting process parameters, which benefits large established vendors whose platforms already conform to emerging standard protocols. Export control regulations under the Bureau of Industry and Security also affect technology transfer decisions for harvesting platform components, creating a mild but growing compliance overhead for multinational players operating manufacturing and R&D operations across U.S. and non-U.S. sites simultaneously.

Competitive Outlook for U.S. Cell Harvesting

By 2032, the U.S. cell harvesting market will be defined by a two-tier competitive structure: a consolidated top tier of three to four fully integrated bioprocessing platform providers commanding premium pricing through closed ecosystem strategies, and a fragmented second tier of specialized niche players competing on price, application specificity, or geography. Thermo Fisher and Sartorius are positioned to extend their dominance through continued acquisition of enabling technologies — particularly in automation software, real-time process analytics, and single-use fluid management — that deepen customer dependency and increase switching costs across both research and commercial manufacturing segments.

Consolidation among mid-tier U.S. players is inevitable as capital requirements for regulatory compliance and product development outpace the financial capacity of independent operators. Repligen Corporation is the most likely acquisition target in the 2025–2027 window given its filtration and single-use component portfolio and existing embedded relationships with top-tier U.S. CDMOs. Strategic acquirers from the diagnostics and life science tools sectors will also enter the market through bolt-on transactions targeting cell therapy-specific harvesting capabilities. Companies that fail to establish consumable revenue annuities and validated GMP workflows at two or more of the top ten U.S. CDMOs by 2027 will face structural margin compression and exit pressure through the remainder of the forecast period.